Hepatic triglyceride and cholesterol synthesis enzymes

Hepatic triglyceride and cholesterol synthesis enzymes" refers collectively to the *family of enzymes in the liver* responsible for synthesizing triglycerides and cholesterol, two major lipid classes critical for energy storage, membrane structure, and signaling. The most prominent cholesterol synthesis enzyme is **HMG-CoA reductase**, the target of statin drugs, which catalyzes the rate-limiting step in cholesterol biosynthesis[2][6]. Key enzymes in triglyceride synthesis include **glycerol-3-phosphate acyltransferase (GPAT)**, **acylglycerol-3-phosphate acyltransferase (AGPAT)**, **phosphatidate phosphatase (Lipin/PAP)**, and **diacylglycerol acyltransferase (DGAT)**, which act sequentially to convert glycerol and fatty acids into triglyceride for storage in lipid droplets[1]. Dysregulation or inhibition of these enzymes is of strong clinical interest for treating cardiovascular and metabolic diseases, although direct inhibitors are far less clinically developed than those for cholesterol synthesis, such as statins.

Other names

Triglyceride synthesis enzymes (hepatic)Cholesterol synthesis enzymes (hepatic)Lipogenic enzymes (hepatic)Hepatic lipogenic enzymes

Inhibition of cholesterol biosynthesis (statins inhibit HMG-CoA reductase); Inhibition of triglyceride synthesis (targeting GPAT, AGPAT, DGAT enzymes, mostly experimental); Promotion of lipid clearance (e.g., modulating hepatic lipase activity)